These results further reinforced our conclusion that anordrin was not involved in the classic nuclear pathway of estrogen regulation and suggested that anordrin may not affect tamoxifen activity to inhibit the growth of ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.